Reports
Global Haemato Oncology Testing Market: By Cancer Type: Laeukemia, Lymphoma, Hodgkin Lymphoma, Others; By Technology: PCR, IHC, NGS, Cytogenetics, Others; By Application; Regional Analysis; Historical Market and Forecast (2024-2032); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments
Global Haemato Oncology Testing Market Outlook
The global haemato oncology testing market is forecast to reach USD 5.49 billion by 2028 from USD 2.45 billion in 2023, growing at a CAGR of 14.6% over the forecast period of 2024-2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Haematological malignancies are among the top ten malignant disorders in terms of incidence rate and cause of death in cancer patients. They collectively make up about 9% of all cancer cases diagnosed in a year. Geneticists provide not only diagnostic tests to haemato oncologists, but also key knowledge of cancer genetics that helps the specialists evaluate their patient’s prognosis, select the most appropriate anticancer therapy, and monitor treatment response.
Market Segmentation
Haemato oncology testing is a test that aids in the diagnosis of blood disease (haematology) and cancer (oncology), further supporting the treatment and prevention of the disease, and providing research into them. Haematology-oncology includes diseases such as iron deficiency anaemia, haemophilia, sickle cell disease, thalassemia, leukaemia, and other organ cancers.
The haemato oncology testing industry can be divided based on segments like cancer type, technology, and application.
The industry can be divided based on cancer type as:
- Leukaemia
- Lymphoma
- Hodgkin Lymphoma
- Others
The industry can be divided based on technology as PCR, IHC, NGS, and cytogenetics, among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry can be broadly categorised based on application into:
- Clinical Laboratories
- Hospitals
- Academic and Research Institutes
- Others
The EMR report looks into the regional markets of haemato oncology testing like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Market Analysis
The global haemato oncology testing market is driven by haematological cancer’s increasing global prevalence, increasing awareness of personalized medicines, and increasing collaborations to develop new assays. On the other hand, it is expected that an uncertain reimbursement scenario will restrict the growth of this market during the forecast period in various regions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The services segment represents the largest proportion of haemato oncology testing. This is mainly due to the growing prevalence and incidence of leukaemia, non-Hodgkin lymphoma, and cancer of myeloma. In addition, the growing awareness of advanced therapies such as personalized medicine also drives this segment’s growth. The growth in the Asia Pacific market is driven primarily by the large patient population, and a growing focus on expanding in this region will drive the industry growth.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global haemato oncology testing market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- F. Hoffmann-La Roche Ltd. [Roche Holding AG]
- Abbott Laboratories
- Qiagen N.V
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- ICON plc
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Cancer Type, Technology, Application, Region |
| Breakup by Cancer Type | Leukaemia, Lymphoma, Hodgkin Lymphoma, Others |
| Breakup by Technology | PCR, IHC, NGS, Cytogenetics, Others |
| Breakup by Application | Clinical Laboratories, Hospitals, Academic & Research Institutes, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | F. Hoffmann-La Roche Ltd. [Roche Holding AG], Abbott Laboratories, Qiagen N.V, Thermo Fisher Scientific Inc., Illumina, Inc. [ILMN (NASDAQ)], Bio-Rad Laboratories, Inc. [BIO (NYSE)], ICON plc, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Haemato Oncology Testing Market Analysis
8.1 Key Industry Highlights
8.2 Global Haemato Oncology Testing Historical Market (2018-2023)
8.3 Global Haemato Oncology Testing Market Forecast (2024-2032)
8.4 Global Haemato Oncology Testing Market by Cancer Type
8.4.1 Laeukemia
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Lymphoma
8.4.2.1 Historical Trend (2018-2023)
8.4.2.3 Forecast Trend (2024-2032)
8.4.3 Hodgkin Lymphoma
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.4 Others
8.5 Global Haemato Oncology Testing Market by Technology
8.5.1 PCR
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 IHC
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 NGS
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Cytogenetics
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Others
8.6 Global Haemato Oncology Testing Market by Application
8.6.1 Clinical Laboratories
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Hospitals
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Academic and Research Institutes
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 Others
8.7 Global Haemato Oncology Testing Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
9 North America Haemato Oncology Testing Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Haemato Oncology Testing Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Haemato Oncology Testing Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Haemato Oncology Testing Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Haemato Oncology Testing Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 F. Hoffmann-La Roche Ltd.
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Abbott Laboratories
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Qiagen N.V
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Thermo Fisher Scientific Inc.
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Illumina Inc.
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Bio-Rad Laboratories, Inc.
15.2.6.1 Company Overview
15.2.6.2 Product Portfolio
15.2.6.3 Demographic Reach and Achievements
15.2.6.4 Certifications
15.2.7 ICON plc
15.2.7.1 Company Overview
15.2.7.2 Product Portfolio
15.2.7.3 Demographic Reach and Achievements
15.2.7.4 Certifications
15.2.8 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Haemato Oncology Testing Market: Key Industry Highlights, 2018 and 2032
2. Global Haemato Oncology Testing Historical Market: Breakup by Cancer Type (USD Million), 2018-2023
3. Global Haemato Oncology Testing Market Forecast: Breakup by Cancer Type (USD Million), 2024-2032
4. Global Haemato Oncology Testing Historical Market: Breakup by Technology (USD Million), 2018-2023
5. Global Haemato Oncology Testing Market Forecast: Breakup by Technology (USD Million), 2024-2032
6. Global Haemato Oncology Testing Historical Market: Breakup by Application (USD Million), 2018-2023
7. Global Haemato Oncology Testing Market Forecast: Breakup by Application (USD Million), 2024-2032
8. Global Haemato Oncology Testing Historical Market: Breakup by Region (USD Million), 2018-2023
9. Global Haemato Oncology Testing Market Forecast: Breakup by Region (USD Million), 2024-2032
10. North America Haemato Oncology Testing Historical Market: Breakup by Country (USD Million), 2018-2023
11. North America Haemato Oncology Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Europe Haemato Oncology Testing Historical Market: Breakup by Country (USD Million), 2018-2023
13. Europe Haemato Oncology Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Asia Pacific Haemato Oncology Testing Historical Market: Breakup by Country (USD Million), 2018-2023
15. Asia Pacific Haemato Oncology Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Latin America Haemato Oncology Testing Historical Market: Breakup by Country (USD Million), 2018-2023
17. Latin America Haemato Oncology Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Middle East and Africa Haemato Oncology Testing Historical Market: Breakup by Country (USD Million), 2018-2023
19. Middle East and Africa Haemato Oncology Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
20. Global Haemato Oncology Testing Market Structure
Key Questions Answered in the Report
In 2023, the global haemato oncology testing market attained a value of nearly USD 2.45 billion.
The market is projected to grow at a CAGR of 14.6% between 2023 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach about USD 5.49 billion by 2032.
The major drivers expected to aid the market growth are the increasing prevalence of haematologic cancer, rising awareness regarding advanced therapies for cancer treatment, preference for personalised medical solutions, improving health care facilities, and growing technological advancements.
The key trends guiding the growth of the market include advancements in diagnostics and testing solutions, growing collaborations and research and development activities, and the development of real time assay kits.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Leukaemia, Lymphoma, and Hodgkin Lymphoma, among others, are the major cancer types in the market.
PCR, IHC, NGS, and cytogenetics, among others, are the significant haemato oncology testing technologies available in the market.
Clinical laboratories, hospitals, and academic and research institutes, among others, are the leading applications of the product in the market.
The key players in the global haemato oncology testing market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Qiagen N.V, Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., and ICON plc, among others.
Analyst Review
The global haemato oncology testing market attained a value of USD 2.45 billion in 2023, driven by the rising incidences of haematologic cancer and the growing awareness regarding its treatment globally. Aided by the growing investment in the research and development activities, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 14.6%. The market is projected to reach USD 5.49 billion by 2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on cancer types, the haemato oncology testing industry can be segmented into leukaemia, lymphoma, and Hodgkin lymphoma, among others. On the basis of technology, the industry is divided into PCR, IHC, NGS, and cytogenetics, among others. By application, the industry is categorised into clinical laboratories, hospitals, and academic and research institutes, among others. The major regional markets for haemato oncology testing are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include F. Hoffmann-La Roche Ltd. [Roche Holding AG], Abbott Laboratories, Qiagen N.V, Thermo Fisher Scientific Inc., Illumina, Inc. [ILMN (NASDAQ)], Bio-Rad Laboratories, Inc. [BIO (NYSE)], ICON plc, Others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER